Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Friday 03 December, 2021

C4X Discovery

Clive Dix wins Scrip Lifetime Achievement Award

RNS Number : 5275U
C4X Discovery Holdings PLC
03 December 2021
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Clive Dix receives the Scrip Lifetime Achievement Award 2021

 

 

3 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), is delighted to announce that its Chief Executive Officer, Dr Clive Dix together with Dame Kate Bingham, the leaders of the UK Vaccine Taskforce, have won the Lifetime Achievement Award at the 2021 Scrip Awards. The Scrip Awards applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare.

 

Eva-Lotta Allan, Chairman of C4X Discovery, said: "We are very proud of this significant achievement by both Clive and Kate and we are thankful for the incredibly important work that they and the whole of the UK Vaccine Taskforce have carried out. Throughout his impressive career, Clive has contributed significantly to the industry and to us, at C4XD, his drive and determination to best serve patients is what makes Clive the great leader and CEO that he is and everyone at C4XD is delighted to see them all recognised through the Scrip Lifetime Achievement Award."

 

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

 

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery .

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUOURRAKUURAA

a d v e r t i s e m e n t